Accelerating development timelines has always been a focus for the biopharmaceutical industry. Most pharma companies perceive being “first to market” as a major advantage over their competitors, as they anticipate high returns by dominating market share. Financial pressures, new competition, and current global healthcare events, such as the COVID-19 pandemic, are further emphasizing the need for you to move quickly as possible into the clinic. Yet, increasing speed may open your drug development program up to additional risks, including added costs and delays, especially if you are relying on unproven platforms and technologies that may not meet the current regulatory guidelines or the unique needs of your target molecule.
By clicking "Access Content" you agree to our Legal Disclaimer and the Lonza Privacy and Cookies Policy.

Latest content
Latest briefing from the Knowledge Center